The Axis, Burden, Coupling interval, Ventricular Tachycardia risk score was found to accurately predict adverse left ventricular remodeling as well as subsequent adverse events in patients with frequent premature ventricular contractions.
The incidence of mortality or disabling stroke 5 years after intervention was comparable in patients at intermediate surgical risk who underwent transcatheter aortic valve replacement or surgery for severe aortic stenosis.
The setting of a target low-density lipoprotein cholesterol level below 70 mg/dL in the 5 years following an ischemic stroke was associated with a 25% reduction in intracranial hemorrhages.
Direct implantation of transcatheter heart valves using third-generation balloon-expandable devices without prior balloon aortic valvuloplasty (BAV) was found to be safe and noninferior to the more conventional approach of transcatheter aortic valve replacement preceded by BAV in patients with severe aortic stenosis.
The incidence of major adverse cardiac events was found to be associated with levels of lipoprotein(a) in patients with diabetes who are prescribed statin medications for coronary artery disease, following percutaneous coronary intervention.
A middle-aged woman with a 15-year history of hereditary transthyretin amyloidosis had a reduction in cardiac amyloid load.
Cardiac magnetic resonance imaging demonstrated moderate-good agreement with measurement of fractional flow reserve in evaluating nonculprit lesions after ST-segment elevation myocardial infarction in reperfused patients with multivessel coronary artery disease.
The use of an intravascular microaxial left ventricular assist device was found to be associated with increased risks for in-hospital mortality and bleeding compared with the use of an intra-aortic balloon pump during percutaneous coronary intervention for acute myocardial infarction complicated by cardiogenic shock.
There are a variety of treatment options available for patients with advance heart failure ineligible for heart transplantation to improve their quality of life, decrease hospitalizations, and potentially improve mortality.
The European-derived high-sensitivity cardiac troponin I assay was found to have high sensitivity and specificity for the ruling out and ruling in, respectively of acute myocardial infarction in patients visiting emergency departments in the United States.
